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Abstract
Background Higher serum sodium concentration has been reported to be a risk factor for the development of incident 
chronic kidney disease (CKD), but its relationship with the progression of established CKD has not been investigated. We 
hypothesised that increased serum sodium concentration is a risk factor for estimated glomerular filtration rate (eGFR) 
decline in CKD.
Methods This was a retrospective cohort study using data collected over a 6-year period, with baseline data obtained during 
the first 2 years. We included patients known to our renal service who had had a minimum of three blood tests every 2 years 
and an eGFR of < 60 mL/min/1.73 m2 at baseline. Exclusion criteria were renal replacement therapy, diabetes mellitus, heart 
failure and decompensated liver disease. A multiple linear regression model investigated the relationship between baseline 
serum sodium and eGFR decline after adjustment for confounding factors.
Results 7418 blood results from 326 patients were included. There was no relationship between serum sodium concentration 
and estimated glomerular filtration rate at baseline. After multivariable adjustment, a 1 mmol/L increase in baseline serum 
sodium was associated with a 1.5 mL/min/1.73 m2 decline in eGFR during the study period (95% CI 0.9, 2.0). A reduction 
in eGFR was not associated with significant changes in serum sodium concentration over 6 years.
Conclusion Higher serum sodium concentration is associated with the progression of CKD, independently of other estab-
lished risk factors. Conversely, significant alterations in serum sodium concentration do not occur with declining kidney 
function.
Keywords Serum sodium · Serum potassium · CKD progression · eGFR decline
Introduction
Higher dietary salt consumption in those with chronic 
kidney disease (CKD) is associated with increased blood 
pressure and proteinuria, independent risk factors for CKD 
progression [1]. The mechanisms underlying the adverse 
effects of salt are incompletely understood, but it has been 
proposed that small increases in serum sodium concentration 
are important [2, 3]. In randomised-controlled trials, acute 
and large alterations in salt intake (ranging from less than 
1 g/day to more than 10 g/day) are associated with parallel 
changes in serum sodium of up to 3 mmol/L [3]. Although 
changes in extracellular volume also occur, a significant pos-
itive correlation between serum sodium and blood pressure 
exists in both animals and humans when volume status is 
controlled using dialysis [4, 5]. In addition, there is in vitro 
evidence that small increases in sodium concentration have a 
direct effect on the vascular endothelium: experiments have 
demonstrated stiffening of endothelial cells, damage to the 
glycocalyx layer and inhibition of nitric oxide release [6, 
7]. Furthermore, increased sodium concentration has been 
shown to induce mRNA expression of many hypertrophy-
related factors, including transforming growth factor-beta 
(TGF-β), that are associated with the progression of CKD 
[8, 9].
Whilst significant abnormalities in serum sodium, espe-
cially hyponatraemia, have been consistently associated with 
mortality in CKD, the influence of small inter-individual 
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differences has largely been ignored [10–13]. Higher serum 
sodium concentrations, within the normal range, have 
recently been reported be a risk factor for the development of 
incident CKD [14, 15]. However, whether there is a relation-
ship between serum sodium and the progression of estab-
lished CKD remains unknown. Therefore, we hypothesised 
that increased serum sodium is a risk factor for renal func-
tion decline and carried out a retrospective analysis to inves-
tigate this. We also considered the possibility that changes 
in serum sodium may occur secondary to CKD progression 
and altered sodium handling by the kidney.
Methods
Study design and population
This was a retrospective cohort study of data collected dur-
ing a 6-year period. The South West Thames Renal Depart-
ment database (Clinical Vision 5.3) was used to identify 
individuals under the follow-up of general nephrology 
services between January 2009 and December 2014. The 
primary outcome was the change in estimated glomerular 
filtration rate (eGFR) over the 6-year study period. In order 
to acutely assess this, the study was separated into three 
2-year periods and only included individuals who had had 
at least three results during each of these periods. Data col-
lected during the first 2-year period was used to determine 
baseline values. Individuals with a mean eGFR of < 60 mL/
min/1.73 m2 at baseline were included in the study. Exclu-
sion criteria were as follows: provision of renal replacement 
therapy during the study period; a diagnosis of congestive 
cardiac failure, diabetes mellitus (type I or II), or decompen-
sated liver disease prior to the study end date.
Data collection
Demographic details and laboratory values were extracted 
from the database and further information was identified 
manually from clinic letters including cause of CKD, co-
morbidity, office blood pressure and medication. Blood test 
results corresponding to the same date for serum sodium, 
potassium, creatinine and haematocrit were obtained and 
an eGFR was calculated for each creatinine value using the 
CKD-EPI equation [16]. Blood samples were processed at 
a number of laboratories in the local area, all of which are 
monitored by the United Kingdom National External Quality 
Assessment Service (NEQAS) to ensure comparable results. 
Serum creatinine was measured by enzymatic assay and 
serum sodium was determined using indirect potentiometry. 
In order to minimise the effect of acute illness or admission 
to hospital, blood tests were excluded from the analysis if 
any of the following applied: the sodium result was missing 
or significantly abnormal (< 125 mmol/L or > 155 mmol/L); 
the sample was taken ≤ 7 days apart from another blood test; 
there was an acute change in creatinine of > 50% from the 
previous baseline.
Baseline laboratory values were determined for each indi-
vidual using the mean test result over the first 2 years of 
the study. Baseline proteinuria was estimated using urine 
protein:creatinine ratio (PCR) and urine albumin:creatinine 
ratio (ACR) results: significant proteinuria was defined as 
a mean PCR of ≥ 50 mg/mmol or a mean ACR of ≥ 30 mg/
mmol. Baseline blood pressure was calculated using the 
mean office measurement from visits during the baseline 
period. Where multiple measurements were recorded for a 
single visit, the lowest reading was used to minimise the 
‘white-coat’ effect. Blood pressure control was defined as 
a mean systolic reading of ≤ 140 mmHg and a mean dias-
tolic reading of ≤ 90 mmHg. Finally, prescription data was 
obtained from nephrology clinic letters during the baseline 
period, using the most recent available medication list.
Statistical analysis
Data were analysed using R version 3.2.1 (2015-06-18) with 
a P value of less than 0.05 being regarded as statistically 
significant. Changes in eGFR (and serum sodium) during 
the 6-year study period were determined for each individual 
using ordinary least squares regression coefficients, with 
time as the independent variable. Baseline analysis was car-
ried out using univariate linear regression to obtain crude 
associations between serum sodium and eGFR, as well as 
other explanatory variables. Differences between two groups 
were analysed using the unpaired Student’s t-test for nor-
mally-distributed variables. Multiple linear regression analy-
sis was used to investigate the relationship between baseline 
serum sodium and eGFR decline, adjusting for potential con-
founding factors (age, sex, race, cause of CKD, blood pres-
sure, proteinuria, baseline eGFR, serum potassium, haema-
tocrit and medications). Blood pressure and proteinuria were 
included as categorical variables because of missing data. 
The model met the assumptions of normality, linearity and 
homoscedasticity, and influential outliers were not identi-
fied. Finally, linear regression was also used to investigate 
changes in serum sodium and potassium with eGFR decline.
Results
Cohort selection and data completeness
Figure 1 demonstrates an overview of the cohort selection 
process. This resulted in 7418 blood tests being included 
in the analysis for 326 individuals. Blood tests were col-
lected over a mean period of 2,014 days (SD 132). For each 
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individual, there was a median of 7 (IQR 5–10) blood tests 
during the baseline period and 13 (IQR 10–19) during the 
follow-up period. Data was complete for age and sex, in 
addition to the blood test results. Non-white ethnicity was 
specified in 30 individuals (9%), and cause of CKD was 
specified in 147 (45%). Baseline blood pressure readings 
were obtained for 279 (86%) of the cohort and baseline pro-
teinuria estimations were available for 243 (75%). Prescrip-
tion data were for available for 278 individuals (85%).
Baseline associations with serum sodium
The baseline characteristics of the cohort are shown in 
Table 1. The mean eGFR was  34.2 mL/min/1.73 m2 (SD 
11.0) and the mean serum sodium concentration was 
139.7 mmol/L (SD 2.0). Univariate regression analysis 
showed a non-significant inverse relationship between eGFR 
and serum sodium at baseline. In comparison, there was a 
significant negative association between eGFR and serum 
potassium (a 1 mmol/L higher serum potassium was associ-
ated with a lower eGFR of − 7.1 mL/min/1.73 m2; 95% CI 
4.3, 9.8). Figure 2 displays the differences in serum sodium 
and potassium by CKD stage.
At baseline, a 1 mmol/L higher serum sodium was associ-
ated with a higher haematocrit of 0.4% (95% CI 0.2, 0.6). 
No relationship between serum sodium and blood pressure 
or proteinuria was demonstrated. The mean serum sodium 
was lower in individuals prescribed diuretics compared to 
those not, but the difference was not significant (139.5 and 
139.9 mmol/L respectively; P = 0.17). There was also no 
significant difference in serum sodium observed with the 
prescription of renin angiotensin system (RAS) inhibitors.
Relationship between baseline serum sodium 
and CKD progression
The mean decline in eGFR during the 6-year study period 
was − 4.2 mL/min/1.73 m2 (SD 10.7). On univariate analysis, 
a 1 mmol/L increase in serum sodium was associated with 
a − 1.4 mL/min/1.73 m2 decline in eGFR during the study 
(95% CI − 2.0, − 0.8). Table 2 displays the results of the mul-
tiple regression model, with change in eGFR during the study 
6,061 patients identified as
under Nephrology follow-up 
(44,178 blood tests)
838 patients had 
 3 blood tests in 
all 3 study periods







 10,894 blood tests excluded for 
being taken  7 days apart
511 patients excluded due to 
study exclusion criteria
49 blood tests + 1 patient 
excluded for missing or 
significantly abnormal results*
6,061 patients identified as
under Nephrology follow-up 
(33,284 blood tests)
5,223 patients excluded for not 
having the minimum number of 
blood tests!
Fig. 1  Flowchart demonstrating an overview of the study cohort 
selection process. *Significantly abnormal result = sodium result of 
< 125 or > 155  mmol/L, or an acute change in creatinine of > 50% 
from the previous baseline
Table 1  Baseline characteristics of study cohort (n = 326)
Data are shown as mean ± standard deviation unless otherwise speci-
fied
CKD chronic kidney disease, eGFR estimated glomerular filtration 
rate (CKD-EPI equation), PCR urine protein:creatinine ratio, ACR 
urine albumin:creatinine ratio, RAS renin:angiotensin system, IQR 
interquartile range
Age in years (median, IQR) 70 (15)
Female sex (n, %) 140 (43)
Non-white ethnicity (n, %) 30 (9)
Cause of CKD (n, %)




 Other renal diagnoses 34 (10)
Laboratory results
 Sodium, mmol/L 139.7 ± 2.0
 Potassium, mmol/L 4.7 ± 0.4
 eGFR, mL/min/1.73 m2 34.2 ± 11.0
 Haematocrit, % 38.6 ± 4.0
Proteinuria (n, %)
 None or low-level 174 (53)
 PCR ≥ 50 or ACR ≥ 30 mg/mmol 69 (21)
 Unknown 83 (26)
Blood pressure control (n, %)
 ≤ 140/90 mmHg 184 (57)
 > 140/90 mmHg 95 (29)
 Unknown 47 (14)
Medications (n, %)
 Loop diuretic 56 (17)
 Thiazide diuretic 54 (17)
 Other diuretic 6 (2)
 RAS inhibitor 193 (59)
 Other antihypertensive agent 167 (51)
 Unknown 48 (15)
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period as the dependent variable. The variables included in 
this model accounted for 27% of the variation in eGFR change. 
Younger age, male gender, non-white ethnicity, proteinuria and 
a lower hematocrit at baseline were all significantly associ-
ated with a decrease in eGFR. In addition, there was a signifi-
cant correlation with serum sodium such that a difference of 
1 mmol/L at baseline was associated with a decline in eGFR of 
− 1.5 mL/min/1.73 m2 during the study (95% CI − 2.0, − 0.9). 
Serum potassium and the prescription of diuretics and/or RAS 
inhibitors were not associated with eGFR loss.
Changes in serum sodium with eGFR decline
The mean difference in serum sodium concentration between 
the baseline period and the final 2 years of the study was 
0.3 mmol/L (SD 1.5). There was a trend for serum sodium 
concentration to decrease with greater reductions in eGFR 
during the study period, but this was not significant (b = 
− 0.02 mmol/L for every − 1 mL/min/1.73 m2 reduction in 
eGFR; 95% CI − 0.04, 0.00). Furthermore, no significant 
relationship was found in a subgroup analysis of individuals 
with an eGFR of < 30 mL/min/1.73 m2 at baseline (n = 132). 
In comparison, for the whole cohort, a decrease in eGFR of 
− 1 mL/min/1.73 m2 was associated with a significant increase 
in serum potassium of 0.02 mmol/L (95% CI 0.01, 0.02).
Discussion
In this study, there was an association between higher 
serum sodium concentration and subsequent eGFR decline. 
After adjustment for confounding variables, a 5 mmol/L 
increase in baseline serum sodium was associated with a 
loss in eGFR of − 7.4 mL/min/1.73 m2 over 6 years in indi-
viduals with established CKD. This finding is interesting 
in that the association occurs within the normal range of 
serum sodium and it supports our primary hypothesis that 
increased serum sodium is a risk factor for CKD progres-
sion. It is also notable because adverse outcomes in CKD, in 
particular mortality, have more frequently been associated 
with hyponatraemia [10–13]. However, we excluded serum 
sodium results during acute illness and in those with signifi-
cant co-morbidity including heart failure. Both may result 
in lower serum sodium and have a confounding influence on 
CKD progression, either as a consequence of decompensated 
disease or the initiation or up-titration of diuretic therapy.
Dietary salt may contribute to higher serum sodium con-
centrations but there was no association between serum 
sodium and blood pressure in this investigation. The use 
of office-based blood pressure readings was a limitation 
in this respect, but there could be alternative explanations 
for the relationship between increased serum sodium and 
eGFR decline. In particular, higher serum sodium could be 
an indicator of reduced extracellular volume, as evidenced 
by the significant positive relationship with haematocrit at 
baseline in our study. Although the effect of serum sodium 
on CKD progression was independent of this, haematocrit is 
a crude marker of hydration state and differences in extracel-
lular volume cannot be excluded. However, at present there 
is limited evidence linking habitual water intake to serum 
sodium concentration or the progression of CKD [17, 18]: in 
the recently published CKD Water Intake Trial, increasing 
water intake did not result in significant alterations in either 
[18]. It is also interesting to speculate as to the potential 
Fig. 2  Boxplots demonstrating serum electrolyte concentrations by 
CKD stage at baseline: a sodium; b potassium. CKD stage 3A cor-
responds to an eGFR of between 45 and 59, stage 3B to an eGFR 
between 30 and 44, and stage 4/5 an eGFR of < 30 mL/min/1.73 m2. 
**P < 0.01; ***P < 0.001 (compared to CKD stage 3A)
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role of vasopressin release that occurs with higher sodium 
concentrations [19]. Following on from animal studies that 
have implicated a causal role for vasopressin in impaired 
renal function, there is a growing body of evidence demon-
strating an association between copeptin levels (a surrogate 
marker of vasopressin) and eGFR decline in those with CKD 
[20, 21].
Finally, we found intra-individual serum sodium to be 
stable over the 6-year study period, consistent with recent 
reports of there being significant individuality in serum 
sodium concentration [22]. We considered the possibility 
that the advancement of CKD could affect the ability of 
the kidneys to regulate salt and water balance, particu-
larly as a greater prevalence of hypernatraemia has been 
reported with progressive stages of CKD [10]. However, 
this study did not find that declining kidney function was 
associated with a significant change in serum sodium. 
There were also no significant alterations in serum sodium 
in a subgroup of individuals with CKD stages 4–5 at base-
line, despite the fact that the capacity to produce concen-
trated urine declines with glomerular filtration rates less 
than 30 mL/min/1.73 m2 [23]. Whilst it is possible that 
the study was underpowered to detect such a change, this 
suggests that our primary findings are not explained by an 
effect of CKD progression on serum sodium.
Limitations
This study has a number of important limitations, includ-
ing a relatively small cohort: the selective design was nec-
essary in order to detect small changes in serum sodium in 
the presence of confounding variables. However, together 
with the retrospective design, this may have resulted in 
selection bias such that those with stable disease or those 
with rapidly progressive disease were excluded. Linear 
regression coefficients were used to estimate eGFR decline 
during the study but non-linear changes over time may 
limit the accuracy of this method. Furthermore, the data 
was collected routinely rather than for research purposes 
and this has implications for completeness and accuracy. 
In particular, there are limitations to using office blood 
pressure readings and prescription data may be unreliable 
due to dose alterations and compliance issues. Finally, 
the confounding effects of unmeasured factors influenc-
ing CKD progression cannot be excluded.
Conclusion
To our knowledge, this study is the first to demonstrate 
an association between higher serum sodium concentra-
tion and subsequent eGFR decline in people with estab-
lished CKD. The observational nature of the study does 
not ascertain causality but, together with evidence that 
dietary salt intake increases serum sodium, this data is 
consistent with guidelines advocating the importance of 
salt restriction in this group. However, inter-individual 
differences in serum sodium concentration are not attrib-
utable to differences in salt intake alone. Further studies 
would be of value to further investigate the link between 
serum sodium, dietary salt, water intake and vasopres-
sin activity, as well as their relationships with long-term 
health outcomes in those with CKD.
Funding None.
Table 2  Multivariate linear regression analysis of factors associated 
with change in eGFR during the 6-year study period
CKD chronic kidney disease, eGFR estimated glomerular filtration 
rate (CKD-EPI equation), PCR urine protein:creatinine ratio, ACR 
urine albumin:creatinine ratio, RAS renin:angiotensin system, CI con-
fidence interval
b 95% CI P value
Age (years) 0.14 0.05, 0.23 < 0.01
Female sex 3.41 1.10, 5.72 < 0.01
Non-white ethnicity − 5.33 − 9.13, − 1.53 < 0.01
Cause of CKD
 Unspecified cause [REF] [REF] [REF]
 Glomerulonephritis/vasculitis − 0.57 − 3.74, 2.61 0.73
 Reflux/obstruction − 0.22 − 4.91, 4.46 0.93
 Renovascular/hypertension 0.36 − 3.34, 4.07 0.85
 Other renal diagnoses − 2.75 − 6.39, 0.89 0.14
Baseline laboratory results
 Baseline sodium (mmol/L) − 1.47 − 2.03, − 0.91 < 0.001
 Baseline potassium (mmol/L) − 0.26 − 3.13, 2.61 0.86
 eGFR (mL/min/1.73 m2) 0.04 − 0.08, 0.16 0.53
 Haematocrit (%) 0.42 0.11, 0.74 < 0.01
Proteinuria
 No proteinuria [REF] [REF] [REF]
 PCR ≥ 50 or ACR ≥ 30 mg/mmol − 4.73 − 7.73, − 1.73 < 0.01
 Unknown 2.22 − 0.45, 4.88 0.10
Blood pressure control
 ≤ 140/90 mmHg [REF] [REF] [REF]
 > 140/90 mmHg 0.22 − 2.29, 2.72 0.87
 Unknown − 2.21 − 6.64, 2.23 0.33
Medications
 Loop diuretic 1.29 − 1.89, 4.46 0.43
 Thiazide diuretic 0.50 − 2.55, 3.55 0.75
 Other diuretic 3.38 − 4.69, 11.44 0.41
 RAS inhibitor − 2.30 − 4.86, 0.27 0.08
 Other antihypertensive agent − 2.17 − 4.63, 0.29 0.08
 Unknown − 1.43 − 6.28, 3.42 0.56
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